Dror Alishekevitz

678 total citations
16 papers, 556 citations indexed

About

Dror Alishekevitz is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Dror Alishekevitz has authored 16 papers receiving a total of 556 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in Dror Alishekevitz's work include Immune cells in cancer (4 papers), Angiogenesis and VEGF in Cancer (4 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Dror Alishekevitz is often cited by papers focused on Immune cells in cancer (4 papers), Angiogenesis and VEGF in Cancer (4 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Dror Alishekevitz collaborates with scholars based in Israel, United States and Switzerland. Dror Alishekevitz's co-authors include Yuval Shaked, Tali Voloshin, David Loven, Svetlana Gingis‐Velitski, Israël Vlodavsky, Neta Ilan, Lilach Gutter-Kapon, Ami Aronheim, Ziv Raviv and Michael Timaner and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Cancer Research and International Journal of Cancer.

In The Last Decade

Dror Alishekevitz

16 papers receiving 555 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dror Alishekevitz Israel	11	270	269	191	103	95	16	556
Rémi Samain France	9	347 1.3×	311 1.2×	153 0.8×	141 1.4×	99 1.0×	12	641
Camille L. Duran United States	12	169 0.6×	347 1.3×	133 0.7×	167 1.6×	124 1.3×	23	646
Reetta Virtakoivu Finland	11	214 0.8×	282 1.0×	165 0.9×	74 0.7×	150 1.6×	19	578
Eslam A. Elghonaimy Egypt	11	273 1.0×	241 0.9×	130 0.7×	103 1.0×	100 1.1×	18	511
Sarah Krause Germany	7	372 1.4×	202 0.8×	175 0.9×	142 1.4×	60 0.6×	10	597
Yasemin Kaygusuz United States	3	439 1.6×	400 1.5×	291 1.5×	176 1.7×	81 0.9×	6	854
Stefano Marastoni Italy	9	110 0.4×	302 1.1×	88 0.5×	113 1.1×	78 0.8×	14	522
Kelly Foley United States	10	357 1.3×	335 1.2×	266 1.4×	124 1.2×	26 0.3×	14	695
Mirella Georgouli United Kingdom	6	149 0.6×	212 0.8×	131 0.7×	101 1.0×	58 0.6×	12	408
Christian Werno Germany	9	127 0.5×	331 1.2×	183 1.0×	246 2.4×	63 0.7×	14	569

Countries citing papers authored by Dror Alishekevitz

Since Specialization

Citations

This map shows the geographic impact of Dror Alishekevitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dror Alishekevitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dror Alishekevitz more than expected).

Fields of papers citing papers by Dror Alishekevitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dror Alishekevitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dror Alishekevitz. The network helps show where Dror Alishekevitz may publish in the future.

Co-authorship network of co-authors of Dror Alishekevitz

This figure shows the co-authorship network connecting the top 25 collaborators of Dror Alishekevitz. A scholar is included among the top collaborators of Dror Alishekevitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dror Alishekevitz. Dror Alishekevitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Alishekevitz, Dror, et al.. (2022). Abstract 654: CD28 shedding is a novel resistance mechanism to anti PD-1 therapy. Cancer Research. 82(12_Supplement). 654–654. 1 indexed citations

Alishekevitz, Dror, Sharon Hashmueli, Rita Greco, et al.. (2022). BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression. Journal for ImmunoTherapy of Cancer. 10(9). e004859–e004859. 26 indexed citations

Alishekevitz, Dror, et al.. (2020). Abstract 2846A: CD28 shedding is a novel immune-regulatory mechanism found in cancer patients which directly inhibits anti PD-1 effect. Cancer Research. 80(16_Supplement). 2846A–2846A. 2 indexed citations

Alishekevitz, Dror, et al.. (2020). Abstract 3266: BND-22, a first-in-class, anti-ILT2 monoclonal antibody inhibits the immunosuppressive effects of HLA-G and enhances anti-tumor activity of immune cells in preclinical in vitro, ex vivo, and in vivo models. Cancer Research. 80(16_Supplement). 3266–3266. 2 indexed citations

Benguigui, Madeleine, Dror Alishekevitz, Michael Timaner, et al.. (2017). Dose- and time-dependence of the host-mediated response to paclitaxel therapy: a mathematical modeling approach. Oncotarget. 9(2). 2574–2590. 8 indexed citations

Alishekevitz, Dror, Svetlana Gingis‐Velitski, Orit Kaidar‐Person, et al.. (2016). Macrophage-Induced Lymphangiogenesis and Metastasis following Paclitaxel Chemotherapy Is Regulated by VEGFR3. Cell Reports. 17(5). 1344–1356. 91 indexed citations

Gutter-Kapon, Lilach, Dror Alishekevitz, Yuval Shaked, et al.. (2016). Heparanase is required for activation and function of macrophages. Proceedings of the National Academy of Sciences. 113(48). E7808–E7817. 87 indexed citations

Beyar‐Katz, Ofrat, Dror Alishekevitz, Michael Timaner, et al.. (2016). Bortezomib‐induced pro‐inflammatory macrophages as a potential factor limiting anti‐tumour efficacy. The Journal of Pathology. 239(3). 262–273. 23 indexed citations

Voloshin, Tali, Dror Alishekevitz, Limor Kaneti, et al.. (2015). Blocking IL1β Pathway Following Paclitaxel Chemotherapy Slightly Inhibits Primary Tumor Growth but Promotes Spontaneous Metastasis. Molecular Cancer Therapeutics. 14(6). 1385–1394. 60 indexed citations

10.

Koren, Lilach, Dror Alishekevitz, Ofer Elhanani, et al.. (2015). ATF3-dependent cross-talk between cardiomyocytes and macrophages promotes cardiac maladaptive remodeling. International Journal of Cardiology. 198. 232–240. 24 indexed citations

11.

Timaner, Michael, Orit Kaidar‐Person, Dror Alishekevitz, et al.. (2015). Dequalinium blocks macrophage-induced metastasis following local radiation. Oncotarget. 6(29). 27537–27554. 30 indexed citations

12.

Timaner, Michael, Dror Alishekevitz, Tsonwin Hai, et al.. (2015). Host JDP2 expression in the bone marrow contributes to metastatic spread. Oncotarget. 6(35). 37737–37749. 8 indexed citations

13.

Hasnis, Erez, Dror Alishekevitz, Tali Voloshin, et al.. (2014). Anti-Bv8 Antibody and Metronomic Gemcitabine Improve Pancreatic Adenocarcinoma Treatment Outcome Following Weekly Gemcitabine Therapy. Neoplasia. 16(6). 501–510. 52 indexed citations

14.

Alishekevitz, Dror, et al.. (2013). Differential Therapeutic Effects of Anti–VEGF-A Antibody in Different Tumor Models: Implications for Choosing Appropriate Tumor Models for Drug Testing. Molecular Cancer Therapeutics. 13(1). 202–213. 13 indexed citations

15.

Aharon, Anat, Svetlana Gingis‐Velitski, Tali Voloshin, et al.. (2013). Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: A process regulated by osteopontin. International Journal of Cancer. 135(2). 270–281. 30 indexed citations

16.

Gingis‐Velitski, Svetlana, David Loven, Liat Benayoun, et al.. (2011). Host Response to Short-term, Single-Agent Chemotherapy Induces Matrix Metalloproteinase-9 Expression and Accelerates Metastasis in Mice. Cancer Research. 71(22). 6986–6996. 99 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact